Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 20,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed Phase 2 Interventional

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793
View directory record Official record
Conditions
Parainfluenza
Interventions
DAS181-F02 Dry Powder in Bulk, DAS181-F02 Nebulized Formulation Inhaled Dose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Duarte, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional

Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

NCT05498493
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Cognitive Rehabilitation, Brain Health Education Program
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 25, 2026, 12:27 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

NCT06869187
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
ABX-002
Drug
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Walnut Creek, California • Cromwell, Connecticut • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04596293
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S or Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Fountain Valley, California • Lancaster, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional Results available

Technology Intensified Diabetes Education Study in African Americans

NCT02088658
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Technology Intensified
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Not yet recruiting Not applicable Interventional

Menstruation and Anemia Research: A Community Health Study

NCT07832526
View directory record Official record
Conditions
Anemia
Interventions
Standard of Care, Informational Series and follow-up support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 55 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
No Longer Available No phase listed Expanded access

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

NCT02715843
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional

Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy

NCT00140491
View directory record Official record
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Vision Restoration Therapy (NOVAVISION)
Device
Lead sponsor
Emory University
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

NCT02625610
View directory record Official record
Conditions
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions
Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
Drug · Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
35
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional

Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study)

NCT01454960
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
Clinical Decision Support: Accountable Justification, Audit and Feedback: Peer Comparison, CDS Order Sets: Suggested Alternatives
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 25, 2026, 12:27 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 25, 2026, 12:27 AM EDT
Active, not recruiting Not applicable Interventional Results available

Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders

NCT05155059
View directory record Official record
Conditions
Functional Movement Disorder
Interventions
MagStim, Sham Comparator
Device · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People

NCT00919724
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional Results available

Spinal Stimulation and Mobility Devices

NCT05520359
View directory record Official record
Conditions
Cerebral Palsy, Stroke, Premature Birth, Hypoxic-Ischemic Encephalopathy, Periventricular Leukomalacia
Interventions
Mobility Device, Spinal Stimulation
Device
Lead sponsor
University of Washington
Other
Eligibility
4 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

NCT02488759
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, Daratumumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 25, 2026, 12:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Testing Pharmacological Therapies for Pregnant Smokers

NCT00224419
View directory record Official record
Conditions
Smoking, Pregnancy
Interventions
Motivational interviewing for smoking cessation, Cognitive behaviors therapy, CBT + NRT
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Durham, North Carolina • Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

NCT00375219
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chiropractic Force Versus Touch

NCT05249530
View directory record Official record
Conditions
Healthy
Interventions
Chiropractic spinal adjustment, Non-force simulation
Other
Lead sponsor
Life University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NCT03977467
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Solid Tumor
Interventions
Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 12:27 AM EDT
Recruiting No phase listed Observational

Evaluation of Hypoxia in Primary Melanoma

NCT06831071
View directory record Official record
Conditions
Melanoma
Interventions
Pimonidazole
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Withdrawn Not applicable Interventional

Philadelphia Immediate Transport in Penetrating Trauma Trial

NCT02821364
View directory record Official record
Conditions
Hemorrhagic Shock, Peritonitis
Interventions
Advanced Life Support
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 25, 2026, 12:27 AM EDT
Completed Not applicable Interventional Results available

A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD

NCT01532999
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Mindfulness Based Stress Reduction, Present Centered Group Therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Tuscaloosa, Alabama • Decatur, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 25, 2026, 12:27 AM EDT
Recruiting Phase 1 Interventional

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 12:27 AM EDT
Recruiting No phase listed Observational

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

NCT07242963
View directory record Official record
Conditions
Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype
Interventions
Not listed
Lead sponsor
Mohammad H. Abu Arja
Other
Eligibility
3 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 12:27 AM EDT